Aldehyde oxidase 1 (AOX1) is a major member of the xanthine oxidase family belonging to the class of complex molybdo-flavoenzymes and plays an important role in the nucleophilic oxidation of N-heterocyclic aromatic compounds as well as various aldehydes. The enzyme has been well known to show remarkable species differences. When comparing the rabbit and monkey enzymes, the former showed extremely high activity towards cinchonidine and methotrxate but the latter exhibited only marginal activities. In contrast, monkey had several times greater activity than did rabbit towards zonisamide and (S)-RS-8359. In this report, we tried to confer high cinchonidine oxidation activity comparable with that of rabbit AOX1 to monkey AOX1. The chimeras generated by restriction enzyme digestion and recombination methods between monkey and rabbit AOX1s indicated that the sequences from N993 to A1088 of rabbit AOX1 are essential for the activity. The kinetic parameters were then measured using monkey AOX1 mutants prepared by site-directed mutagenesis. The monkey V1085A mutant acquired the high cinchonidine oxidation activity. Inversely, the reciprocal rabbit A1081V mutant lost the activity entirely; amino acid 1081 of rabbit AOX1 corresponding to amino acid 1085 of monkey AOX1. Thus, cinchonidine oxidation activity was drastically changed by mutation of a single residue in AOX1. However, this might be true for bulky substrates such as cinchonidine, but not for small substrates. The mechanism of substrate-dependent species differences in AOX1 activity towards bulky substrates is discussed.
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Introduction
Aldehyde oxidase (AO, EC 1.2.3.1) is a major member of the xanthine oxidase family belonging to the molybdo-flavoenzymes (MFEs) together with xanthine oxidoreductase (XOR; xanthine dehydrogenase (XD) form, EC 1.1.1.204; xanthine oxidase (XO) form, EC 1.1.3.22) (Beedham 1985 (Beedham , 1987 (Beedham , 1998 (Beedham , 2002 Kitamura et al., 2006; Garattini et al., 2008; Schumann et al., 2009) . AOX1 consists of a homodimer with a subunit molecular mass of about 150 kDa. Each subunit is made up of a 20 kDa N-terminal domain containing two different 2Fe-2S clusters in which reducing equivalents necessary for catalysis are stored, a 40 kDa central domain containing a flavin adenine dinucleotide (FAD), and an 85 kDa C-terminal domain containing a molybdenum cofactor (MoCo) in which a substrate binding site is located (Garattini et al., 2008) . Substrates are oxidized via Mo-OH by base-assisted hydroxylation at the MoCo center, the Mo being reduced from Mo(Ⅵ) to the MO(Ⅳ) state. MO(Ⅳ) is re-oxidized via rapid one-electron transfer to the Fe-S cluster and further intramolecular electron transfer to FAD. FADH 2 is finally re-oxidized by molecular oxygen to produce a superoxide anion and hydrogen peroxide via either a one-electron or a two-electron transfer. The enzyme catalyzes the nucleophilic, but not electrophilic, oxidation of a wide range of endogenous and exogenous aldehydes and N-heterocyclic aromatic compounds. In addition, the enzyme can also catalyze the reductive-ring cleavage metabolism of the atypical antipsychotic drug ziprasidone in humans (Prakash et al., 1997; Beedham et al., 2003) .
Being fundamentally different from XOR, AOX1-catalyzed drug metabolism results in marked species differences, which have been well documented for methotrexate (Jordan et al., 1999; Kitamura et al., 1999) , This article has not been copyedited and formatted. The final version may differ from this version. famciclovir (Rashidi et al., 1997) , cinchona alkaloids (Beedham et al., 1992; Itoh et al., 2006) , zonisamide (Kitamura et al., 2001) , and a monoamine oxidase A inhibitor RS-8359 (Itoh et al., 2005 , 2006 Takasaki et al., 1999 Takasaki et al., , 2005 . As a rule, AOX1 activity is high in monkey and human, moderate to low in rabbit, rat, and mouse, and deficient in dog. This might be due to the amount of enzyme present in the liver. However, this order happens to change depending on the substrate structure used and might be difficult to explain based on the quantitative difference of the enzyme. For example, when monkey and rabbit are compared, the following considerably complicated situation seems to arise. Approximately two orders of magnitude higher methotrexate 7-hydroxylase activity was shown in rabbit compared with that of monkey (Kitamura et al., 1999) . Similarly, rabbit exhibited two to three orders of magnitude higher activity towards cinchonidine 2'-oxidation than did that of monkey (Itoh et al., 2006) . In contrast, roughly one order of magnitude higher AOX1-catalyzed zonisamide reduction activity was observed in monkey compared to that of rabbit (Kitamura et al., 2001) . Monkey had more than several times greater (S)-RS-8359 2-oxidation activity than did rabbit (Itoh et al., 2006) . Thus, the two species show remarkably different catalytic properties from each other depending on the substrate structures employed as already documented by Beedham (2002) , Kitamura et al. (2006) and Garattini et al. (2008) . The reversal of order in AOX1 activities depending on substrate structure might be primarily due to structural differences in the active sites.
MFEs have a large molecular mass with the active site buried inside (approximately 10-15Å from the surface) that substrates can access through a funnel-shaped cavity (Garattini et al., 2003) . The tunnel is wider at the surface (15-20Å in diameter) and narrower at mid-height in close proximity to the Mo atom This article has not been copyedited and formatted. The final version may differ from this version. (2Å in diameter). Substrate specificity and inhibition studies suggest that the tunnel may vary even in different AO isozymes (Garattini et al., 2008) . Accordingly, it is expected that some amino acid in the tunnel might be responsible for the reversed species difference seen between monkey and rabbit.
Enzyme manipulation using recombinant or site-directed mutagenesis (SDM) techniques could be an excellent way of characterizing important properties of targeted enzymes. In the present study, we constructed mutant AOX1 cDNAs by substituting nucleotides of monkey AOX1 with relevant ones of rabbit AOX1, and prepared AOX1 mutant proteins by expressing them in Escherichia coli (E. coli).
Analyses of their catalytic characteristics revealed that a single amino acid substitution of V1085A in monkey AOX1 resulted in a drastic change of substrate specificity towards cinchonidine. Inversely, the rabbit AOX1 A1081V mutant completely lost its high cinchonidine oxidation activity. The mechanism of the interesting substrate-dependent species differences will be discussed in detail. Table 1 . In addition, twelve monkey and one rabbit mutant AOX1 cDNAs were prepared using the synthetic oligonucleotides listed in Table 2 as the mutagenic primers. The resulting chimeric and mutant constructs were verified by complete sequence analysis. They were then subcloned in the expression vector pQE-30Xa (Qiagen, Hilden, Germany) and used to transform competent E. coli M15 cells (Qiagen).
Materials and Methods

Chemicals
This article has not been copyedited and formatted. The final version may differ from this version. Volume of Substrate Molecule. For predicting the bulkiness of the substrate molecules, the volume of the substrate molecule was computed using the Hartree-Fock/6-31G* basis set implemented in Spartan'06 software (Wavefunction Inc., Japan Branch Office, Tokyo, Japan).
Statistical Analysis. All expression experiments were conducted three times, and data are presented as the mean ± SD. The kinetic parameters were determined by nonlinear regression analysis using SigmaPlot 11.0 software (Systat Softare Inc., Chicago, IL, USA). Significant difference was evaluated by Student's t-test using SPSS 11.5 software; a p value of <0.05 was considered statistically significant.
Results
Expression of Chimera and Mutant Proteins of Monkey AOX1.
In this study, the chimera proteins refer to those derived from the cDNA generated by restriction enzyme digestion and recombination methods and the mutant proteins to those generated by SDM techniques. The expressed proteins in E. coli This article has not been copyedited and formatted. The final version may differ from this version. 
Kinetic Parameters for Cinchonidine and (S)-RS-8359 by Monkey and Rabbit Wild-type AOX1.
The oxidation activities of cinchonidine and (S)-RS-8359 were measured using monkey and rabbit wild-type AOX1 proteins expressed in E. coli. The kinetic parameters analyzed by Eadie-Hofstee plots are shown in Table 3 . Rabbit AOX1 had an extremely high Vmax value towards cinchonidine, whereas no substantial activity was detected in monkey enzyme. When (S)-RS-8359 served as a substrate, the Vmax value observed in monkey AOX1 was approximately twice that in rabbit AOX1. Because the kinetic parameters were calculated by the use of purified enzymes, the results were considered to suggest that the remarkable species differences in cinchonidine oxidation activity were essentially due to qualitative differences in the structure of the active site of AOX1 rather than quantitative differences in the enzyme that is generally thought to be a major mechanism of species differences. Thus, the AOX1 chimera proteins between monkey and rabbit are considered useful for the study of the structural analysis of the active site. chimera proteins were prepared by exchanging the sequences of monkey AOX1 with those corresponding to rabbit AOX1, as shown in Fig. 2 , and their kinetic parameters were determined (Table 3 ). Chimera 1, in which the N-terminus half of monkey AOX1 was substituted by that of rabbit AOX1, had no activity. In contrast, chimera 2, in which the C-terminus half of monkey AOX1 was replaced by that of rabbit AOX1,
showed a high degree of activity similar to that of wild-type rabbit AOX1. To narrow down the regions responsible for the catalytic activity towards cinchonidine, three chimera proteins were produced by substituting about one-third of the C-terminus half of monkey AOX1 with those of rabbit AOX1. The substituted amino acid sequences were from T616 to F859 in chimera 3, from F859 to A1092 in chimera 4, and from A1092 to the C-terminus in chimera 5 (Fig. 2) . As is shown in Table 3 , only chimera 4 was found to exhibit exceedingly high activity, whereas the other two chimera proteins showed no activity at all.
Furthermore, the amino acid areas from F859 to A1092 of monkey AOX1 were divided into three parts to which those of rabbit AOX1 were introduced. The substituted amino acid sequences were from F859 to M955 in chimera 6, from M955 to N997 in chimera 7, and from N997 to A1092 in chimera 8. Only chimera protein 8 exhibited remarkably high cinchonidine oxidation activity; the other two did not (Table   3 ).
The kinetic parameters for the oxidation activities of (S)-RS-8359 are also listed in Table 3 
Kinetic Parameters for Cinchonidine and (S)-RS-8359 by Monkey Mutant AOX1. The amino acid
areas from N997 to A1092 of rabbit AOX1 were revealed to be of primary importance for exertion of its catalytic activity towards cinchonidine. Within the areas, eleven amino acid residues were different from monkey AOX1 and four of them were different from those of human and rat AOX1s as well (Fig. 3 ) (Wright et al., 1993; Calzi et al., 1995; Wright et al., 1999; Huang et al., 1999) . Accordingly, the following four sets of mutant proteins were prepared by SDM as being the most likely ones to endow monkey AOX1 with high cinchonidine oxidation activity: mutant 1 with the K1004Q mutation, mutant 2 with the M1009I mutation, mutant 3 with the A1023T mutation, and mutant 4 with the I1032V mutation (Table 2) .
Unexpectedly, those mutants did not have any detectable activity towards cinchonidine, although their (S)-RS-8359 oxidation activities were comparable to those of wild-type monkey AOX1 (Table 4) . Nevertheless, the amino acid sequences from N997 to A1092 of rabbit AOX1 should certainly contain the key amino acid(s) responsible for the superb substrate specificity towards cinchonidine. Therefore, the mutant proteins were prepared by continuous substitutions of every two amino acids from the N-terminus end of the crucial eleven amino acids (Table 2) . Mutants 5~9 substituted from K1004 to I1067 did not express any cinchonidine oxidation activity, but mutant 10 with both A1083T and V1085A mutations This article has not been copyedited and formatted. The final version may differ from this version. showed high activity ( Table 4 ), suggesting that the solution questioned here ultimately narrowed down to the two amino acid residues of A1083 and V1085. To learn which one was the determinant or whether both were needed, the two mutants were produced as follows: mutant 11 with the A1083T mutation and mutant 12 with the V1085A mutation. Mutant 11 revealed a similar extent of high cinchonidine oxidation activity to that of wild-type rabbit AOX1; there was no detectable activity in mutant 12 (Table 5) . On the contrary, (S)-RS-8359 oxidation activity was confirmed in each mutant protein, and a larger Km value was seen for mutant 11 retaining high cinchonidine oxidation activity than that of mutant 12, which lacked such activity.
The results clearly indicated that a single substitution of valine with alanine at position 1085 of monkey AOX1 can dramatically change monkey AOX1 to rabbit type AOX1 as to substrate specificity towards cinchonidine.
TABLE 5
Kinetic Parameters for Cinchonidine and (S)-RS-8359 by Rabbit Mutant AOX1 A1081V. It was
supposed that the reciprocal mutation of rabbit AOX1 by substituting alanine 1081 with valine converts it to an enzyme that resembles monkey AOX1 as far as cinchonidine oxidation activity is concerned. Table 5 shows that mutant 13 with mutation A1081V completely lost the high cinchonidine oxidation activity.
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Discussion
As a rule, AOX1 activity is higher in monkey and human, medium to low in rabbit, guinea pig, rat, and mouse, and deficient in dog. However, rabbit shows approximately two orders of magnitude greater oxidation activity towards cinchonidine and methotrexate than do the other species. The species differences in the substrates might be mostly caused by differences in the structures of the active site of AOX1 and not by differences in the amount of enzyme present in the liver. To verify this hypothesis in the current report, we aimed to change the substrate specificity towards cinchonidine of monkey AOX1 to that of rabbit type AOX1 using genetic engineering methods. Two hundred and twenty one amino acids of monkey and rabbit
AOX1s are different from each other. Therefore, the chimera proteins were first prepared to focus on the region of interest by the method of restriction enzyme digestion and recombination followed by preparation of mutant proteins by SDM to isolate the amino acid responsible for the phenomenon.
The results of measuring cinchonidine oxidation activity by the monkey chimera AOX1 proteins clearly displayed that the range from N993 to A1088 of rabbit AOX1, which corresponds to N997 to A1092 of monkey AOX1 because of the shortage of four amino acids of rabbit AOX1 in the hinge between the FAD and MoCo domains (Huang et al., 1999; Hoshino et al., 2007) , is central to the for exertion of cinchonidine oxidation activity. Among the 95 amino acid sequences present in the region, 11 are different from each other in monkey and rabbit AOX1s. The one that is essential for cinchonidine oxidation activity was determined using monkey mutant AOX1 proteins. Consequently, substituting valine at position 1085 of This article has not been copyedited and formatted. The final version may differ from this version. reported for aldehyde dehydrogenase 3 (ALDH3) by Ho et al. (2008) . They found that removing the methyl group of threonine in the T186S mutant of ALDH3 enables the bulky aldophosphamide to bind better, and to be a poorer enzyme when small substrates such as benzaldehyde derivatives were used. In rabbit AOX1, the small size of A1081 plays an important role in determining a suitable shape for bulky substrates, and the substitution of valine with alanine in monkey AOX1 dramatically improved the oxidation activity towards bulky cinchonidine.
Compared with cinchonidine, when a little smaller and more planar molecule (S)-RS-8359 was used as a substrate, the kinetic parameters were slightly complicated. The monkey mutant V1085A showed a similar large Vmax value to that of the wild-type monkey protein, but the Km value increased from 12.3 not shown). Thus, it can be said that substrate specificity of human AOX1 is highly similar to that of monkey. However, a wide range of substrates including small molecules such as benzaldehyde and vanillin in addition to (S)-RS-8359 and large molecules such as methotrexate and retinal in addition to cinchonidine should be investigated to clarify the role of the amino acid at the relevant position. Results for those substrates might be useful for a better understanding of the structure of the active site of AOX1. Such investigation will be an interesting subject for future study.
In conclusion, the monkey mutant V1085A AOX1 protein provided high cinchonidine oxidation activity, whereas the reciprocal rabbit mutant A1081V AOX1 protein completely lost the activity. The results suggest that the size of the amino acid at the relevant positions is critical for oxidation towards bulky substrates and that this is the reason for species differences toward those substrates.
